Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? by Ana Oaknin, Isabelle Ray-Coquard, Domenica Lorusso, Susana Banerjee

Get full text

Advances in immunotherapy for cervical cancer by Juan Francisco Grau-Bejar, Carmen Garcia-Duran, David Garcia-Illescas, Oriol Mirallas, Ana Oaknin

Get full text

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways by Michael J. Birrer, Keiichi Fujiwara, Ana Oaknin, Leslie Randall, Laureen S. Ojalvo, Christian Valencia, Isabelle Ray-Coquard

Get full text

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion by Philipp Harter, Ana Oaknin, Isabelle Ray-Coquard, Domenica Lorusso, Kathleen N Moore, Antonio Gonzalez-Martin, Susana Banerjee

Get full text

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer by Victor Rodriguez-Freixinos, Fiorella Ruiz-Pace, Lorena Fariñas-Madrid, Ana Christina Garrido-Castro, Guillermo Villacampa, Paolo Nuciforo, Ana Vivancos, Rodrigo Dienstmann, Ana Oaknin

Get full text

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors by Andres Poveda, Ana Oaknin, Ignacio Romero, Angel Guerrero-Zotano, Lorena Fariñas-Madrid, Victor Rodriguez-Freixinos, Pedro Mallol, Raquel Lopez-Reig, Jose Antonio Lopez-Guerrero

Get full text

Management of advanced ovarian cancer in Spain: an expert Delphi consensus by Andres Redondo, Ana Oaknin, Maria Jesus Rubio, Maria-Pilar Barretina-Ginesta, Ana de Juan, Luis Manso, Ignacio Romero, Cristina Martin-Lorente, Andres Poveda, Antonio Gonzalez-Martin

Get full text

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study by Andres Poveda, Raquel Lopez-Reig, Ana Oaknin, Andres Redondo, Maria Jesus Rubio, Eva Guerra, Lorena Fariñas-Madrid, Alejandro Gallego, Victor Rodriguez-Freixinos, Antonio Fernandez-Serra, Oscar Juan, Ignacio Romero, Jose A. Lopez-Guerrero

Get full text

370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial by Ana Oaknin, Maria-Pilar Barretina-Ginesta, Victor Moreno, Thierry André, Ruth Plummer, Florence Joly, Rowan Miller, Joanna Pikiel, Susana Banerjee, Jose Manuel Trigo Perez, Bhavana Pothuri, Andrea Jewell, Anna Tinker, Dominique Berton, Susan Ellard, Jennifer Veneris, Tao Duan

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade by Octavio A. Romero, Andrea Vilarrubi, Juan J. Alburquerque-Bejar, Antonio Gomez, Alvaro Andrades, Deborah Trastulli, Eva Pros, Fernando Setien, Sara Verdura, Lourdes Farré, Juan F. Martín-Tejera, Paula Llabata, Ana Oaknin, Maria Saigi, Josep M. Piulats, Xavier Matias-Guiu, Pedro P. Medina, August Vidal, Alberto Villanueva, Montse Sanchez-Cespedes

Get full text

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable... by Lucy Gilbert, Ana Oaknin, Prafull Ghatage, Rebecca Kristeleit, Wei Guo, Sharad Ghamande, Valentina Boni, Jubilee Brown, Xinwei Han, Vanessa Samouëlian, Ellie Im, Renaud Sabatier, Anna V Tinker, David M O’malley, Bhavana Pothuri, Cara Mathews, Jennifer Veneris, Tao Duan, Linda Duska, Joshua Press, Charles Leath III, Sybil Zildjian

Get full text

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease... by Ana Oaknin, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Susana Banerjee, Jesus García‐Donas, Elizabeth M. Swisher, Terri Cameron, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman

Get full text

Laboratory Cross-Comparison and Ring Test Trial for Tumor <i>BRCA</i> Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study by Zaida Garcia-Casado, Ana Oaknin, Marta Mendiola, Gorka Alkorta-Aranburu, Jose Ramon Antunez-Lopez, Gema Moreno-Bueno, Jose Palacios, Alfonso Yubero, Raul Marquez, Alejandro Gallego, Ana Beatriz Sanchez-Heras, Jose Antonio Lopez-Guerrero, Cristina Perez-Segura, Pilar Barretina-Ginesta, Jesus Alarcon, Lydia Gaba, Antonia Marquez, Judit Matito, Juan Cueva, Isabel Palacio, Maria Iglesias, Angels Arcusa, Luisa Sanchez-Lorenzo, Eva Guerra-Alia, Ignacio Romero, Ana Vivancos

Get full text

The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study by Antonio Fernández-Serra, Raquel López-Reig, Raúl Márquez, Alejandro Gallego, Luís Miguel de Sande, Alfonso Yubero, Cristina Pérez-Segura, Avinash Ramchandani-Vaswani, María Pilar Barretina-Ginesta, Elsa Mendizábal, Carmen Esteban, Fernando Gálvez, Ana Beatriz Sánchez-Heras, Eva María Guerra-Alía, Lydia Gaba, María Quindós, Isabel Palacio, Jesús Alarcón, Ana Oaknin, Jessica Aliaga, Marta Ramírez-Calvo, Zaida García-Casado, Ignacio Romero, José Antonio López-Guerrero

Get full text

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) by Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S. Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin K. Lin, Iain A. McNeish

Get full text

716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or ga... by Jean-Yves Blay, Antoine Italiano, Stephane Champiat, Paolo Antonio Ascierto, Manish Sharma, Jeeyun Lee, Luis Paz-Ares Rodriguez, Keun-Wook Lee, Yoon-Koo Kang, Drew Rasco, Edith A Perez, Mariano Ponz-Sarvise, Lu Xu, Jean-Philippe Spano, Coya Tapia, Ecaterina Dumbrava, Kathleen Moore, Jason Ptacek, Michele Magni, Alfonso Cortes Salgado, Ming Yin, Agnese Losurdo, Antoine Deleuze, Mark D Pegram, Ardaman Shergill, Alexander I Spira, Michael N Alonso, Joan Albanell Mestres, Marta GilMartin, Arielle Heeke, Ana Oaknin Benzaquen, Ignacio Ortego Zabalza, Haeseong Park, Cecile Vicier, Ivan Victoria, Benjamin Weinberg, Bob T Li